Estimating the 95% confidence interval for survival gain between an experimental anti-cancer treatment and a control
暂无分享,去创建一个
[1] A. Messori. Survival curve fitting using the Gompertz function: a methodology for conducting cost-effectiveness analyses on mortality data. , 1997, Computer methods and programs in biomedicine.
[2] A. Messori,et al. Median versus mean lifetime survival in the analysis of survival data. , 1997, Haematologica.
[3] W. Henley,et al. Improved curve fits to summary survival data: application to economic evaluation of health technologies , 2011, BMC Medical Research Methodology.
[4] N. Welton,et al. Survival time outcomes in randomized, controlled trials and meta-analyses: the parallel universes of efficacy and cost-effectiveness. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[5] A. Forastiere. VALUE BASED CANCER CARE , 2011 .
[6] M C Weinstein,et al. Gains in life expectancy from medical interventions--standardizing data on outcomes. , 1998, The New England journal of medicine.
[7] G. Guyatt,et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.
[8] A. Messori,et al. Pharmacoeconomic profile of paclitaxel as a first‐line treatment for patients with advanced ovarian carcinoma: A lifetime cost‐effectiveness analysis , 1996, Cancer.